disappearance of pleural effusion and ascites, absence of enlarged lymph nodes and normalized liver and spleen. Three courses of R-COP were given as maintenance therapy. After that, the patient went home without need for further steroids or immunosuppressants therapy. He remained disease-free and maintained good functional status on his last follow-up at 7 years after initial diagnosis.
CD is a heterogenous group of lymphoproliferative disorders characterized by a hyperplastic-reactive process involving the immune system. CD complicated with SLE is a rare clinical condition with only a few cases [1] [2] [3] reported. Although autoimmune thrombocytopenia (AITP) was seen in nearly 50% of these patients, the severity was mostly mild to moderate, while severe thrombocytopenia at the onset of disease (before chemotherapy) has not been previously reported. Thrombocytopenia was our major concerns during treatment as it did not respond to potent chemotherapy. Although the use of rituximab in SLE is still controversial, its efficacy in CD [4] and AITP [5] has been reported. Moreover, its success in treating our patient suggests a potential role of rituximab in treating similar patients. 
